S. Soule

When not to treat--chemotherapy for small (< or = 1 cm) breast cancers.

S. Soule, 2004, Breast disease.

Adjuvant chemotherapy for tumors of one centimeter or less: The law of diminishing returns

K. Miller, S. Soule, 2001, Current oncology reports.

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

G. Sledge, P. Giannakakou, K. Sanders, 2005, Cancer research.

Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.

G. Sledge, L. Einhorn, R. Zon, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue

M. Cronin, G. Sledge, S. Shak, 2007, Breast Cancer Research and Treatment.

Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory

G. Hutchins, G. Sledge, K. Kopecky, 2004, Breast Cancer Research and Treatment.

A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer

G. Sledge, K. Miller, L. Lenaz, 2004, Investigational New Drugs.

HER-2/neu expression in germ cell tumours

K. Miller, L. Cheng, G. Vance, 2002, Journal of clinical pathology.

Handbook of Advanced Cancer Care: Osteosarcoma and Ewing's sarcoma

S. Soule, D. Seitz, 2003 .